4.7 Article

SGC-GAK-1: A Chemical Probe for Cyclin G Associated Kinase (GAK)

Journal

JOURNAL OF MEDICINAL CHEMISTRY
Volume 62, Issue 5, Pages 2830-2836

Publisher

AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.8b01213

Keywords

-

Funding

  1. AbbVie [1097737]
  2. Bayer Pharma AG
  3. Boehringer Ingelheim
  4. Canada Foundation for Innovation
  5. Eshelman Institute for Innovation
  6. Genome Canada
  7. Innovative Medicines Initiative (EU/EFPIA) [ULTRA -DD Grant] [115766]
  8. Janssen
  9. Merck KGaA Darmstadt Germany
  10. MSD
  11. Novartis Pharma AG
  12. Ontario Ministry of Economic Development and Innovation
  13. Pfizer
  14. Sao Paulo Research Foundation-FAPESP
  15. Takeda
  16. Wellcome [106169/ZZ14/Z]
  17. Mass Spectrometry Core Laboratory at the University of North Carolina at Chapel Hill

Ask authors/readers for more resources

We describe SGC-GAK-1 (11), a potent, selective, and cell-active inhibitor of cyclin G-associated kinase (GAK), together with a structurally related negative control SGC-GAK-1N (14). 11 was highly selective in an in vitro kinome-wide screen, but cellular engagement assays defined RIPK2 as a collateral target. We identified 18 as a potent RIPK2 inhibitor lacking GAK activity. Together, this chemical probe set can be used to interrogate GAK cellular biology.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Pharmacology & Pharmacy

Chemistry-led investigations into the mode of action of NAMPT activators, resulting in the discovery of non-pyridyl class NAMPT activators

Siyuan Tang, Miguel Garzon Sanz, Oliver Smith, Andreas Kraemer, Daniel Egbase, Paul W. Caton, Stefan Knapp, Sam Butterworth

Summary: The cofactor NAD thorn plays a crucial role in physiological processes and enhancing healthy aging. Recent studies have shown that NAMPT activators can increase NAD thorn levels and have beneficial effects. The structure activity relationships of these activators were evaluated and it was hypothesized that they act via a through-water interaction in the NAMPT active site, leading to the design of a urea-class NAMPT activator with similar or greater activity compared to known analogues.

ACTA PHARMACEUTICA SINICA B (2023)

Article Chemistry, Multidisciplinary

Discovery of Potent and Exquisitely Selective Inhibitors of Kinase CK1 with Tunable Isoform Selectivity

Vaclav Nemec, Prashant Khirsariya, Pavlina Janovska, Paula Martin Moyano, Lukas Maier, Petra Prochazkova, Pavlina Kebkova, Tomas Gybel', Benedict-Tilman Berger, Apirat Chaikuad, Maria Reinecke, Bernhard Kuster, Stefan Knapp, Vitezslav Bryja, Kamil Paruch

Summary: In this study, a new class of potent and highly selective inhibitors of CK1 alpha, delta and epsilon were identified. MU1250, MU1500 and MU1742 were selected as quality chemical probes for those CK1 isoforms due to their optimal in vitro and in vivo profiles and exclusive selectivity. Furthermore, it was found that the central 1H-pyrrolo[2,3-b]pyridine-imidazole pharmacophore can be used as the basis of highly selective inhibitors of other therapeutically relevant protein kinases, such as p38 alpha.

ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2023)

Article Cell Biology

SGC-CAMKK2-1: A Chemical Probe for CAMKK2

Carrow Wells, Yi Liang, Thomas L. Pulliam, Chenchu Lin, Dominik Awad, Benjamin Eduful, Sean O'Byrne, Mohammad Anwar Hossain, Carolina Moura Costa Catta-Preta, Priscila Zonzini Ramos, Opher Gileadi, Carina Gileadi, Rafael M. Counago, Brittany Stork, Christopher G. Langendorf, Kevin Nay, Jonathan S. Oakhill, Debarati Mukherjee, Luigi Racioppi, Anthony R. Means, Brian York, Donald P. McDonnell, John W. Scott, Daniel E. Frigo, David H. Drewry

Summary: This study presents a selective small molecule probe, SGC-CAMKK2-1, that specifically targets CAMKK2, which can be used to investigate the therapeutic benefits of CAMKK2 inhibition.

CELLS (2023)

Article Biochemistry & Molecular Biology

Development of Cell Permeable NanoBRET Probes for the Measurement of PLK1 Target Engagement in Live Cells

Xuan Yang, Jeffery L. Smith, Michael T. Beck, Jennifer M. Wilkinson, Ani Michaud, James D. Vasta, Matthew B. Robers, Timothy M. Willson

Summary: PLK1 is a protein kinase that regulates mitosis and is an important target for oncology drugs and potential antitarget for drugs against DNA damage response pathway or anti-infective host kinases. A new energy transfer probe called Probe 11 was developed to include PLK1 in live cell NanoBRET target engagement assays. This probe enabled the measurement of potency of known PLK inhibitors and investigation of the promiscuity of adavosertib as a dual PLK1/WEE1 inhibitor. The results showed selective engagement of WEE1 at clinically relevant doses.

MOLECULES (2023)

Article Chemistry, Medicinal

Design and Synthesis of Pyrazole-Based Macrocyclic Kinase Inhibitors Targeting BMPR2

Jennifer A. Amrhein, Guiqun Wang, Benedict-Tilman Berger, Lena M. Berger, Amalia D. Kalampaliki, Andreas Kraemer, Stefan Knapp, Thomas Hanke

Summary: Bone morphogenetic protein (BMP) signaling is mediated by heterotetramers formed by type-I and type-II receptors. Upon BMP binding, the constitutively active type-II receptors activate type-I receptors, leading to SMAD effector protein phosphorylation. Most drug development on receptor tyrosine kinase-like (TKL) family has focused on targeting type-I receptors, with only a few inhibitors against type-II receptors. BMPR2 is involved in multiple diseases, including pulmonary arterial hypertension, Alzheimer's disease, and cancer. This study reports the development of a selective and potent BMPR2 inhibitor 8a through macrocyclization of a promiscuous inhibitor 1 based on a 3-amino-1H-pyrazole hinge binding moiety.

ACS MEDICINAL CHEMISTRY LETTERS (2023)

Article Multidisciplinary Sciences

A host defense peptide mimetic, brilacidin, potentiates caspofungin antifungal activity against human pathogenic fungi

Thaila Fernanda dos Reis, Patricia Alves de Castro, Rafael Wesley Bastos, Camila Figueiredo Pinzan, Pedro F. N. Souza, Suzanne Ackloo, Mohammad Anwar Hossain, David Harold Drewry, Sondus Alkhazraji, Ashraf S. Ibrahim, Hyunil Jo, Jorge D. Lightfoot, Emily M. Adams, Kevin K. Fuller, William F. deGrado, Gustavo H. Goldman

Summary: This study demonstrates the synergistic activity of the host defense peptide mimetic brilacidin with caspofungin against various fungal strains, including those that are resistant to caspofungin. These findings suggest that the combination of brilacidin with antifungal drugs currently in clinical use can improve the treatment outcome of aspergillosis and other fungal infections.

NATURE COMMUNICATIONS (2023)

Article Multidisciplinary Sciences

Modulation of tau tubulin kinases (TTBK1 and TTBK2) impacts ciliogenesis

Frances M. M. Bashore, Ariana B. B. Marquez, Apirat Chaikuad, Stefanie Howell, Andrea S. S. Dunn, Alvaro A. A. Beltran, Jeffery L. L. Smith, David H. H. Drewry, Adriana S. S. Beltran, Alison D. D. Axtman

Summary: Tau tubulin kinase 1 and 2 (TTBK1/2) are highly homologous kinases that play important roles in brain-related pathways. TTBK1 is involved in diseases like Alzheimer's disease and amyotrophic lateral sclerosis, while TTBK2 is critical for cilia assembly. In this study, a targeted library was designed to identify chemical tools that can inhibit TTBK1 and TTBK2 and affect downstream signaling. Compound 10 was found to significantly reduce primary cilia expression in human induced pluripotent stem cells (iPSCs), confirming the role of TTBK2 in ciliogenesis.

SCIENTIFIC REPORTS (2023)

Review Biochemistry & Molecular Biology

How many kinases are druggable? A review of our current understanding

Brian Anderson, Peter Rosston, Han Wee Ong, Mohammad Anwar Hossain, Zachary W. Davis-Gilbert, David H. Drewry

Summary: This article analyzes data on human kinases, including citation count, availability of chemical probes, approved and investigational drugs, PDB structures, and biochemical and cellular assays. The analysis reveals that many kinases are understudied and there is untapped potential for further development. The article also discusses different strategies for generating selectivity between kinases. In conclusion, the authors believe it is possible to develop a tool compound for every human kinase.

BIOCHEMICAL JOURNAL (2023)

Article Chemistry, Multidisciplinary

Targeting the Alternative Vitamin E Metabolite Binding Site Enables Noncanonical PPARγ Modulation

Silvia Arifi, Julian A. Marschner, Julius Pollinger, Laura Isigkeit, Pascal Heitel, Astrid Kaiser, Lennart Obeser, Georg Hoefner, Ewgenij Proschak, Stefan Knapp, Apirat Chaikuad, Jan Heering, Daniel Merk

Summary: The lipid-sensing transcription factor PPAR γ can bind to antidiabetic TZD drugs, oxidized vitamin E metabolites, and vitamin E mimetic garcinoic acid. While the effects of the second binding on PPAR γ activity are unclear, a selective ligand of the second site has been developed, revealing potential noncanonical regulation of PPAR γ activities. This alternative binding diminishes FOXO signaling and may have therapeutic applications.

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2023)

News Item Biochemistry & Molecular Biology

Improving data quality in chemical biology

Stefan Knapp, Susanne Mueller

Summary: The quality and appropriate use of chemical tools play a crucial role in determining the quality and reliability of scientific data based on their utilization. Two papers now extend criteria to new modalities and critically review adherence to established guidelines.

NATURE CHEMICAL BIOLOGY (2023)

Article Biochemistry & Molecular Biology

Structure of LRRK1 and mechanisms of autoinhibition and activation

Janice M. Reimer, Andrea M. Dickey, Yu Xuan Lin, Robert G. Abrisch, Sebastian Mathea, Deep Chatterjee, Elizabeth J. Fay, Stefan Knapp, Matthew D. Daugherty, Samara L. Reck-Peterson, Andres E. Leschziner

Summary: Leucine Rich Repeat Kinase 1 and 2 (LRRK1 and LRRK2) are homologs in the ROCO family of proteins in humans. Despite their shared domain architecture and involvement in intracellular trafficking, they have strikingly different disease associations, with LRRK2 linked to Parkinson's disease and LRRK1 linked to bone diseases.

NATURE STRUCTURAL & MOLECULAR BIOLOGY (2023)

Article Chemistry, Multidisciplinary

Optimization of 3-Cyano-7-cyclopropylamino-pyrazolo[1,5-a]pyrimidines toward the Development of an In Vivo Chemical Probe for CSNK2A

Xuan Yang, Han Wee Ong, Rebekah J. Dickmander, Jeffery L. Smith, Jason W. Brown, William Tao, Edcon Chang, Nathaniel J. Moorman, Alison D. Axtman, Timothy M. Willson

Summary: During the development of analogues of 3-cyano-7-cyclopropylamino-pyrazolo[1,5-a]pyrimidines, it was discovered that phase II conjugation by GST enzymes played a major role in the metabolic transformation in hepatocytes. A protocol involving co-dosing with ethacrynic acid was developed to enhance the exposure of the analogues in mice.

ACS OMEGA (2023)

Article Biochemistry & Molecular Biology

Tracking the PROTAC degradation pathway in living cells highlights the importance of ternary complex measurement for PROTAC optimization

Martin P. Schwalm, Andreas Kraemer, Anja Doelle, Janik Weckesser, Xufen Yu, Jian Jin, Krishna Saxena, Stefan Knapp

Summary: Cell-based assays using NanoLuciferase and HaloTag were developed to measure the kinetics and stability of PROTAC-induced degradation and ternary complex formation. Characterization of PROTACs targeting WDR5 revealed the importance of ternary complex formation and stability in the early degradation cascade. Comparison of ternary complex crystal structures highlighted the significance of an efficient E3-target interface for ternary complex stability. This study provides a strategy for the rational optimization of PROTACs using a series of live cell assays monitoring key steps of the early PROTAC-induced degradation pathway.

CELL CHEMICAL BIOLOGY (2023)

Article Chemistry, Medicinal

Structure-Based Development of Isoform-Selective Inhibitors of Casein Kinase 1ε vs Casein Kinase 1δ

Jun Yong Choi, Yoshihiko Noguchi, James M. Alburger, Simon Bayle, Eugene Chung, Wayne Grant, Apirat Chaikuad, Stefan Knapp, Derek R. Duckett, William R. Roush

Summary: Specific inhibition of a single kinase isoform is challenging due to the high conservation of ATP-binding sites. A potent and highly CK1 epsilon-isoform-selective inhibitor (SR-4133) was developed by comparing the X-ray crystal structures of CK1 delta and CK1 epsilon. The selective inhibition of CK1 epsilon is achieved by the stable binding of SR-4133 in the ATP-binding pocket of CK1 epsilon.

JOURNAL OF MEDICINAL CHEMISTRY (2023)

Article Biochemistry & Molecular Biology

Synthesis and Biological Evaluation of 2-Substituted Quinazolin-4(3H)-Ones with Antiproliferative Activities

Maria Karelou, Dionysis Kampasis, Amalia D. Kalampaliki, Leentje Persoons, Andreas Kraemer, Dominique Schols, Stefan Knapp, Steven De Jonghe, Ioannis K. Kostakis, Sotiris S. Nikolaropoulos

Summary: Sixteen new 2-substituted quinazolines were synthesized and evaluated for their anti-proliferative activity against multiple cancer cell lines. Compound 17 showed remarkable activity against the majority of tested cell lines.

MOLECULES (2023)

No Data Available